Background Image

Leveraging Microneedle Particles to Advance the Next Generation of Skin Health Solutions

Johnson & Johnson Innovation, Asia Pacific, recently announced that it has facilitated a research collaboration between Dr. Ci:Labo Co., Ltd. and Raphas Co., Ltd.—a Korean-based company specializing in microneedle patches—for the exclusive development and application of the microneedle particles under Raphas’ patented Droplet Extension (DEN) technology in skin care products.

Raphas’ unique DEN technology manufactures microneedle particles for the improvement of penetrating active ingredients into the skin. It’s use with soluble materials; a low manufacturing temperature and short processing time makes the microneedle competitive for skin health applications.

Under the terms of the agreement, Dr. Ci:Labo will work closely with Raphas to co-develop and modify the technology platform to produce individual microneedle particles which can be dispensed in one single application to the face. The collaboration will also explore the application of microneedle particles in a liquid formulation with select Dr. Ci:Labo topical skincare products to enhance the transdermal delivery of active ingredients.

Johnson & Johnson Innovation’s close partnership with Raphas began in 2018 following a collaboration between Raphas and NeoStrata to launch Exuviance HA100 Micro Filler, a dissolvable microneedle patch. Since then, the microneedle technology has evolved into the next generation of skin health solutions, from patches for spot treatment to particles for the entire face. The long-term history with Raphas is a testament of the company’s efforts in developing a revolutionary first-in-class cosmetic product for consumers.

If you are working on early-stage research, solutions or technologies in consumer health or any of our cross-sector focus areas, submit your request below for a chance to discuss with the team!


Cautions Concerning Forward-Looking Statements

This announcement contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to a new collaboration and product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Consumer Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges inherent in new product development, including the uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. Johnson & Johnson Consumer Inc. and Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.